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Korean guidelines for nonsteroidal anti-inflammatory drug 
(NSAID)-induced peptic ulcer were previously developed in 
2009 with the collaboration of the Korean College of Helico-
bacter and Upper Gastrointestinal Research and Korean So-
ciety of Gastroenterology. However, the previous guidelines 
were based mainly upon a review of the relevant literature 
and expert opinion. Therefore, the guidelines need to be 
revised. We organized a guideline Development Commit-
tee for drug-related peptic ulcer under the auspices of the 
Korean College of Helicobacter and Upper Gastrointestinal 
Research in 2017 and developed nine statements, includ-
ing four for NSAIDs, three for aspirin and other antiplatelet 
agents, and two for anticoagulants through a de novo pro-
cess founded on evidence-based medicine that included 
a literature search and a meta-analysis, A consensus was 
reached through the application of the modified Delphi 
method. The primary target of these guidelines is adult pa-
tients undergoing long-term treatment with NSAIDs, aspirin 
or other antiplatelet agents and anticoagulants. The revised 
guidelines reflect the expert consensus and is intended to 
assist clinicians in the management and prevention of drug-
induced peptic ulcer and associated conditions. (Gut Liver 
2020;14:707-726)
Key Words: Peptic ulcer; Non-steroidal anti-inflammatory 
agents; Antiplatelet agent; Anticoagulants; Guideline
INTRODUCTION
Korea has the world’s most rapidly aging population, and 
the prevalence of chronic diseases like osteoarthritis or cerebro-
vascular diseases and the corresponding financial burden on 
individuals and society are increasing rapidly.1,2 Furthermore, as 
nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin or other 
antiplatelet agents or anticoagulants continue to be used as a 
primary therapeutic agent for chronic diseases, primary care 
physicians frequently experience drug-induced gastrointestinal 
(GI) side effects. These include GI damage such as peptic ulcer 
(PU) or bleeding.3 Previous large-scale randomized control stud-
ies showed that the annual incidence of upper GI clinical events, 
which included uncomplicated symptomatic PU, by use of non-
selective NSAID ranged from 2.7% to 4.5%, and that of major 
complications such as bleeding or perforation ranged from 1.0% 
to 1.5%,4-7 and other pivotal studies have shown that aspirin 
is the most potent risk factor for GI bleeding when combined 
with other antiplatelet agents, such as clopidogrel.8,9 A previ-
ous Korean multicenter cohort study showed that prevalence of 
Helicobacter pylori infection in Korea decreased significantly 
from 59.4% to 45.9% during the period from 1995 to 2005. In 
contrast, the incidence of PU and gastric ulcer (GU) increased 
significantly during that same period, while that of duodenal 
ulcer (DU) did not significantly change, which suggests that a 
portion of the PU seen, was caused by NSAID or aspirin rather 
than H. pylori infection during the period of aging popula-
tion.10 A recent retrospective Korean study showed that old age 
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and major comorbidity were significant risk factors for NSAID-
associated PU perforation.11 In summary, drug-related PU often 
occurs among the elderly with comorbidities, and sometimes is 
expected to contribute to the development of serious complica-
tions such as bleeding and perforation. Thus, it is important 
to identify the clinical characteristics of drug-related PU and 
develop clinical practice guidelines for its appropriate treatment 
and prevention. 
Clinical practice guidelines for drug-related PU were previ-
ously developed and published in the United States (American 
College of Gastroenterology),12 Canada (Canadian Association 
of Gastroenterology)13 and Japan (Japanese Society of Gastro-
enterology).14 Previously, Korean guidelines for prevention and 
treatment of NSAID-related PUs,15 as well as diagnosis for PU 
disease,16 treatment for non-bleeding PU disease,17 treatment 
for bleeding PU disease18 and treatment for PU disease under 
special conditions,19 were developed under the auspices of the 
Korean College of Helicobacter and Upper GI Research and the 
Korean Society of Gastroenterology in 2009. However, these 
previous guidelines were criticized for the lack of evidence 
produced by systematic literature review as well as multidis-
ciplinary approach, and were closer to expert opinions rather 
than evidence-based clinical practice guidelines. Revised clini-
cal practice guidelines primarily focused on the prevention and 
treatment of drug-related PU considering its prevalence and 
severity, and produced by evidence-based guideline statements 
based on a de novo process was needed to overcome the limita-
tions of previous guidelines. 
The main target population of this clinical practice guideline 
is adult patients with long-term administration of NSAIDs, as-
pirin or other antiplatelet agents or anticoagulants, who have 
a history of drug-related PU and its complications or who cor-
respond to a high-risk group. In particular, this clinical practice 
guideline actively reflects the contents of questions about the 
selection or resumption of drugs, which were frequently asked 
by patients who visited the outpatient department of gastro-
enterology, or who had undergone inpatient treatment due to 
PU and its complications during the long-term administration 
of NSAIDs, aspirin or antiplatelet agents or anticoagulants. The 
purpose of this clinical practice guideline therefore, is to sum-
marize the risk factors for drug-related PU and to provide ap-
propriate guidelines for the prevention and treatment of drug-
related PUs and its complications in patients with long-term 
use of NSAIDs, aspirin or other antiplatelet agents and antico-
agulants. It is to be hoped that this guideline, will help clini-
cians make decisions at the outpatient department of primary 
medical institutions. Furthermore, the authors aimed to provide 
specific guidelines for gastroenterologists, as well as orthopedic 
surgeons, rheumatologists, cardiologists, neurologists and other 
related specialists who frequently prescribe NSAIDs, aspirin or 
other antiplatelet agents, or anticoagulants, to effectively man-
age PU and its complications in the course of outpatient and in-
patient treatment at secondary and tertiary medical institutions. 
The authors’ intent was also to provide educational materials 
for medical workers such as doctors and nurses in training, and 
to enhance the predictability of medical services and help them 
choose optimal treatments by providing the best standards for 
clinical care. Through all of these efforts, the authors intended 
to improve the quality of life of patients and contribute to im-
proving national health.
This clinical practice guideline is a specific and comprehen-
sive recommendation for the treatment of drug-related PU. 
This guideline was written as evidence-based recommendations 
rather than a list of textbook knowledge. However, in areas of 
clinical significance and where expert opinions are consistent, 
recommendations have been made by agreement even though 
there was a lack of specific evidence in the literature.
DEVELOPMENT PROCESS OF THE CLINICAL PRACTICE 
GUIDELINE
1. Organization of the guideline committee and multidisci-
plinary team
The clinical guideline practice committee was composed of 
the Steering Committee, the Development Committee and the 
Appraisal Committee. The Steering Committee established the 
strategy and direction of guidance development, appointed the 
relevant chairperson, and reviewed and approved the project 
budget. The Steering Committee also coordinated stakeholders 
in the development of the guideline and supervised the main-
tenance of editorial independence. The Development Commit-
tee was established under the Korean College of Helicobacter 
and Upper GI Research, and consisted of 14 gastroenterologists 
from 11 universities (general chairman: Yong Chan Lee; com-
mittee chairman: Byung-Wook Kim; secretary: Moon Kyung 
Joo; members: Beom Jin Kim, Joon Sung Kim, Jae Myung Park, 
Chan Hyuk Park, Chang Seok Bang, Ji Yong Ahn, Hyo-Joon 
Yang, Bong Eun Lee, Jeong Hoon Lee, Hye-Kyung Jung, and 
Yu Kyung Cho). Two methodology experts (Hyun Jung Kim and 
Ein Soon Shin) conducted workshops in each part of the devel-
opment process of the guideline (Preparation for Revising Clini-
cal Practice Guidelines and Systematic Literature Review [July 
12, 2017] and Qualification of Literature Using Review Manager 
[RevMan, the Nordic Cochrane Centre, Copenhagen, Denmark; 
December 21, 2017]) to provide training on the methodology 
for developing clinical practice guidelines, and the commit-
tee developed this guideline consistent with the principles of 
evidence-based medicine. The Appraisal Committee consisted of 
three members, and two gastroenterologists who did not partici-
pate in the development of the guideline conducted peer review 
for external evaluation. To ensure this was a multidisciplinary 
process, the following academic societies participated in the de-
velopment of the guideline: the Korean Society of Gastroenter-
ology, the Korean Society of Cardiology, the Korean Society of 
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Pathologists, the Korean Gastric Cancer Association, the Korean 
Society of Pediatric Gastroenterology, Hepatology and Nutri-
tion, the Korean Physician’s Association. Since the first meeting 
was held on June 14, 2017, a total of 12 committee meetings, 
two workshops and one off-line and one on-line Delphi vote 
were conducted through August 2018, to produce draft recom-
mendations.
2. Development process of clinical practice guideline
The Development Committee reviewed previous Korean guide-
lines on the prevention and treatment of NSAID-related PU15 
and other related guidelines16-19 which were developed under 
supervision of the Korean College of Helicobacter and Upper GI 
Research and the Korean Society of Gastroenterology in 2009. A 
decision was made to develop the guidelines to cover the treat-
ment and prevention of drug-related PU and its complications 
caused by NSAID, aspirin or other antiplatelet agents or antico-
agulants specifically, from among the total available informa-
tion on diagnosis, treatment and prevention of PU. Furthermore, 
considering the criticism that previous guidelines had been 
closer to experts’ opinions rather than evidence-based clinical 
practice guideline, the Development Committee proceeded with 
a de novo method, which newly selected key questions and 
drew recommendations for key questions through systematic lit-
erature review and quality assessment, and excluded individual 
expert opinion as much as possible. 
1) Selection of key questions
The selection of key questions for the clinical practice guide-
lines were made primarily with the participation of all members 
of the Development Committee, and were finalized in consider-
ation of external guidelines and domestic clinical practice. The 
key clinical questions for each subject were selected following 
the principle of PICO (Population, Intervention, Comparison, 
Outcome), and systematic literature searches were conducted on 
the basis of PICO (Supplementary Table 1).
2) Literature search
Literature from January 1987 to November 2017 was sys-
temically searched using three bibliographic databases (MED-
LINE, EMBASE, and Cochrane Library) and a search engine 
(KoreaMed). We searched the literature with a combination of 
population-related index words (NSAID, aspirin, antiplatelet 
agent, anticoagulant, and PU) and intervention-related index 
words (proton pump inhibitor [PPI], microprostol, histamine-2 
receptor antagonist [H2RA], and H. pylori eradication) (Supple-
mentary Table 2). The selection criteria applied to literature were 
as follows: (1) studies of adults over 18 years; and (2) original 
articles, and exclusion criteria were as follows: (1) editorials; (2) 
letters, brief reports or syllabi; (3) case reports; or (4) abstracts. 
The Development Committee requested web search by providing 
index words to a librarian who majored in literature and infor-
mation science, and duplicate literature was excluded through 
cross-search. After initial screening of literature that did not 
meet the selection/exclusion criteria based on the title and ab-
stract, the full text of the screened literature was carefully read 
and the literature that met the selection/exclusion criteria was 
finally selected. Two independent reviewers reviewed the full 
text, and a literature was selected if both reviewers agreed that 
it was corresponding to the subject. However, if the decisions 
did not coordinate, the final decision was made after discussion 
by the whole Development Committee.
3) Quality assessment of literature and meta-analysis
The selected literature was qualified by Cochrane Collabora-
tion’s Tool for Assessing the Risk of Bias if it was a randomized 
controlled trial (RCT),20 and by Risk of Bias Assessment tool 
for Non-randomized Studies (RoBANS)21 in the case of non-
randomized trial. Two reviewers evaluated the literature inde-
pendently, and if there was disagreement among reviewers, the 
final decision was made either by discussion or by arbitration of 
a third party. The effect of specific interventions on the results 
were presented as odds ratio (OR) or relative risk (RR) with 95% 
confidence interval (CI), respectively, using the RevMan (version 
5.3.3) and the Comprehensive Meta-analysis Software 3.0 (Bio-
stat, Englewood, NJ, USA) programs. The results of each meta-
analysis were summarized using Forest plot, and the publication 
bias of the studies was evaluated by funnel plot. Heterogeneity 
was evaluated by I2 test, which was calculated by the following 
equation: I2 (%)=100×(Q-df)/Q (Q=chi-square statistic, df=degree 
of freedom). I2 values exist between 0 and 100%, with a greater 
homogeneity at less than 25%, a moderate degree at 50%, and a 
higher degree of heterogeneity at 75%. 
4) Extraction of recommendations and decisions on strength 
of recommendation and level of evidence
Based on the results of meta-analysis, 11 draft recommen-
dations were initially made; six were about NSAID, three for 
aspirin, two for anticoagulants. Strength of recommendation 
and level of evidence were decided using GRADE (Grading of 
Recommendations Assessment, Development and Evaluation, 
http://www.gradeworkinggroup.org). Strength of recommenda-
tion was classified according to 5 grades: (1) strong for; (2) weak 
for; (3) strong against; (4) weak against; (5) insufficient (Table 
1), and level of evidence as 4 grades: (1) high; (2) moderate; (3) 
low; (4) very low (Table 2). Then, downgrade or upgrade of level 
of evidence were considered according to the following criteria: 
In the case of RCT, the level of evidence was downgraded one 
or two grades if there was (1) risk of bias; (2) inconsistency; (3) 
indirectness; (4) imprecision; and (5) publication bias existed; 
and in case of observational study, the level of evidence was 
upgraded one or two grades if, (1) large effect magnitude ex-
isted; (2) if dose response existed, and (3) all plausible residual 
confounding and bias would reduce a demonstrated effect.22 The 
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strength of recommendation was determined by considering not 
only the level of evidence but also the magnitude of the effect 
(the balance between benefit and harm), patients’ preferences 
and values, the use of resources, and the possibility of domestic 
application of the level of evidence. Members of the Develop-
ment Committee decided on the wording and strength of the 
recommendations through face-to-face meetings or discussions 
via e-mail, taking into account the balance between the favor-
able and unfavorable outcomes of intervention, the quality of 
evidence, patients’ values and preferences, feasibility, and ben-
efits and risk factors.
5) Agreement and acceptance of recommendations
After draft recommendations were extracted, the Develop-
ment Committee invited academic experts representing the 
main user population of the related drugs, and adopted the 
recommendations using modified Delphi method. The experts 
who participated as members of the panel were as follows: cur-
rent and former chairmen, secretary general and director and 
members of Scientific Committee of the Korean College of Heli-
cobacter and Upper GI Research, and board members represent-
ing the Korean Society of Gastroenterology, the Korean Society 
of Cardiology, the Korean Society of Pathologists, the Korean 
Gastric Cancer Association, the Korean Society of Pediatric Gas-
troenterology, Hepatology and Nutrition and the Korean Physi-
cian’s Association. Before the vote, the panel was sent an e-mail 
with recommendations and supporting documents so that they 
could read the contents in advance and judge independently. 
On the day of the vote, members of the Development Commit-
tee announced the recommendations, evidences, strength of 
recommendations and level of evidence, and at the end of the 
presentation, the panels conducted an anonymous vote using 
an electronic keypad. The degree of agreement on the draft 
recommendations was determined as follows using a 5-point 
Likert scale: (1) completely agree; (2) mostly agree; (3) partially 
agree; (4) mostly disagree; (5) completely disagree; (6) not sure. 
If the number of votes of agreement from combining (1) and (2) 
was more than two-thirds of the total number of votes cast, the 
recommendation was considered an agreement. Immediately 
after the vote on each recommendation, the panels discussed 
the evidence for supporting the recommendation and benefits 
and harms. Of the 11 recommendations, nine were adopted as 
a result of the first round of voting, while two were dismissed, 
which also failed to obtain the consent of more than two-thirds 
on the second round of online voting and finally were rejected. 
Therefore, it was decided that the nine recommendations had 
been finally agreed upon.
6) External review
Each member of the Development Committee in charge of 
each recommendation prepared a manuscript of the details by 
referring to the key questions, the process of extracting recom-
mendations, the evidence within the literature and the minutes. 
Two experts (Gwang Ho Baik and Kee Don Choi) in the field of 
gastroenterology related to PUs who did not directly participate 
in the development, objectively verified the draft manuscript 
Table 1. Strength of Recommendation
Strength of recommendation Interpretation
Strong for The benefit of the intervention is greater than the harm and the level of evidence is high, which is strongly 
recommended in most clinical situations.
Weak for The benefit of the intervention may vary depending on the clinical situation of the intervention or the patient/
social value, and is recommended to be used selectively or conditionally.
Strong against The harm of the intervention is greater than the benefit and the level of evidence is high or the size of effec-
tiveness is unclear and the level of evidence is low, which is recommended not to be used.
Weak against The harm of the intervention may vary depending on the clinical situation of the intervention or the patient/
social value, and is recommended not to be used selectively or conditionally.
Insufficient Evidence to judge the size of effectiveness of the intervention or the level of evidence is insufficient, and it is 
not possible to decide whether or not to recommend until further research evidence is accumulated.
Table 2. Level of Evidence
Quality level Interpretation
High We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate We are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a 
possibility that it is substantially different.
Low Our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect.
Very low We have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect.
Joo MK, et al: Clinical Guidelines for Drug-Related Peptic Ulcer  711
prepared by the Development Committee. The points identified 
in peer reviews were modified and reflected through the second 
internal discussion process. For external review by a group of 
experts, a draft of the clinical practice guideline, which included 
nine adopted and two dismissed recommendations, was pre-
sented to the 200 members of the academic society composed 
of specialists in gastroenterology at the 2018 annual autumn 
PG Course of the Korean College of Helicobacter and Upper GI 
Research, and opinions were collected through open discus-
sion. The Development Committee confirmed again that it was 
not appropriate to adopt the two dismissed recommendations 
as final recommendations in this clinical practice guideline, re-
flecting the opinion that the studies related to the two dismissed 
recommendations (the preventive effect of misoprostol on long-
term NSAID users; the preventive effect of H2RA on long-term 
NSAID users) were mostly conducted a long time ago, and that 
the two drugs in question were not routinely used in actual 
clinical practice.
7) Financial support for development of the clinical prac-
tice guideline and independence of development
Although this guideline was developed on the academic 
society’s own budget without external financial support, the 
Development Committee operated independently of the Korean 
College of Helicobacter and Upper GI Research. Furthermore, 
throughout the development of the guideline, funding and fi-
nancial support from the academic society have not directly, 
indirectly, or potentially affected the content of the guideline or 
the process used to develop the guideline. All the members of 
the Development Committee were investigated as follows to en-
sure that they had no conflicts of interest or potential conflicts 
and, in fact, no conflicts of interest arose during their participa-
tion in the guidelines development: (1) if a member received 
more than 10 million won in sponsorship or compensation for 
a topic related to the development of the guideline in the past 2 
years; (2) if a member has experience in conducting related re-
search with funding from a specific institution or pharmaceuti-
cal company; (3) if the right to economic benefits, such as share 
interests, is provided by the agency concerned with the devel-
opment of the guideline; (4) if an official or unofficial title has 
been provided by the agency concerned with the development 
of the guidelines; (5) if a member owned intellectual property 
rights for drugs related to the development of the guideline. The 
Development Committee intended to ensure confidence in the 
editorial independence by submitting the above in writing.
8) Future plans for dissemination, distribution, and revision
This guideline was certified by the Korean Medical Associa-
tion (KMA) in June 2020 and it was included in the information 
center for clinical practice guideline of the KMA website (https://
www.guideline.or.kr/). In addition, the Development Commit-
tee intends to publish this guideline in the Korean Journal of 
Gastroenterology and international medical journals related to 
gastroenterology, and to post it on the website of the associated 
academic society, Twitter, and Facebook so that any clinician 
can easily download and use it. The Development Committee 
also intends to register and publicize it on the website of the 
Korean Association of Internal Medicine, and to produce pam-
phlets composed of a summary of the guideline and distribute 
them actively through future academic events. After distribu-
tion, this clinical practice guideline will be used as a basis for 
the treatment and care of patients at each level of medical 
institutions and nursing institutions, as well as presented as a 
seminar on conservative education of academic organizations 
related to drug-related PUs, for training of human resources 
for health and medical workers, and dissemination of medical 
knowledge for patients and caregivers.
For proper supervision and evaluation of the implementation 
of this guideline, a survey on whether the recommendations 
are implemented will be conducted on members of the Korean 
College of Helicobacter and Upper GI Research in the future, 
and the results of the survey will be announced on the society’s 
website. Furthermore, the Scientific Committee and the Research 
Affairs of the Korean College of Helicobacter and upper GI re-
search will monitor the study outcomes and future foreign clini-
cal practice guidelines related to NSAIDs, aspirin or other anti-
platelet agents, or anticoagulants, and will revise this guideline 
every 3 to 5 years if new research results are accumulated and it 
is deemed necessary to add to, or change recommendations.
CONSENSUS STATEMENTS
Statement 1. High-risk factors of NSAID-induced PU and its 
complications include old age, a history of PU, administra-
tion of high-dose NSAIDs, and co-administration of aspi-
rin, antiplatelet agent, or steroid. We recommend checking 
patients’ past history and their medications to prevent PU 
and its complications in patients who receive NSAID medi-
cation.
Strength of recommendation: strong for, level of evidence: low
Expert opinion: completely agree (74%), mostly agree (22%), 
partially agree (0%), mostly disagree (4%), completely dis-
agree (0%), not sure (0%)
The risk factors of PU and its complication in patients who 
receive NSAID medications have been reported in the secondary 
analysis of RCTs and in several observational studies.23-28 A pro-
spective study by Laine et al.28 demonstrated that age ≥65 years, 
a history of PU, and co-administration of low-dose aspirin (LDA) 
were major associated factors for PU and its complications in 
patients taking NSAIDs. In a retrospective cohort study by Lee et 
al.25 on the risk factors of NSAID-induced gastropathy, age ≥60 
years was the most important risk factor. A case-control study 
by García Rodríguez and Jick24 identified that old age, smoking 
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habit, a history of PU, and co-administration of anticoagulant or 
steroid, in addition to a history of PU bleeding, were risk factors 
of upper GI bleeding. Among the risk factors of PU bleeding, a 
history of PU complication was the highest risk factor (RR, 13.5; 
95% CI, 10.3 to 17.7), and followed by multiple NSAID use (RR, 
9.0; 95% CI, 5.7 to 14.2), co-administration of anticoagulant (RR, 
6.4; 95% CI, 2.8 to 14.6) and an uncomplicated PU history (RR, 
6.1; 95% CI, 5.1 to 7.3). Additionally, the risk of NSAID-induced 
PU bleeding increases as patients’ age increases. The RR (95% 
CI) for PU bleeding was 1.6 (1.4 to 2.0) in 50s, 3.1 (2.5 to 3.7) 
in 60s, and 5.6 (4.6 to 6.9) in 70s compared to individuals who 
were 25 to 49 years.24 The significant risk of old age for NSAID-
induced PU may be due to the high tendency of daily NSAID 
medication in older people.29
Therefore, we should know that the risk of PU and its compli-
cations are increased if patients are old, have a history of PU, or 
use multiple NSAIDs, aspirin, antiplatelet agent, anticoagulant, 
or steroid. In these cases, we also need an effort to prevent PU.
Statement 2. We recommend that patients scheduled for 
long-term NSAID therapy undergo testing for, and treat-
ment of, H. pylori infection in order to prevent PU and its 
complications.
Strength of recommendation: strong for, level of evidence: high
Expert opinion: completely agree (88%), mostly agree (0%), 
partially agree (8%), mostly disagree (0%), completely dis-
agree (0%), not sure (4%)
Benefit: preventive effect on PU and its complications
Harm: increase of antibiotic-resistant H. pylori strain
Six RCTs compared the effect of H. pylori eradication for de-
creasing NSAID-related PU (Supplementary Fig. 1).30-35 Overall, 
H. pylori eradication significantly reduced the occurrence of 
NSAID-related PU compared with non-eradication (pooled RR, 
0.54; 95% CI, 0.31 to 0.94) (Supplementary Fig. 2). However, 
this effect was inconsistent in subgroup analysis based on the 
exposure history of NSAID, and H. pylori eradication was more 
effective for decreasing PUs in NSAID-naïve patients (pooled 
RR, 0.27; 95% CI, 0.14 to 0.53) (Supplementary Fig. 3),30-32 but 
not in chronic NSAID users (pooled RR, 0.92; 95% CI, 0.58 to 
1.46) (Supplementary Fig. 4).33-35 In addition, the effect of H. 
pylori eradication for reductions in PU-related complications 
was also inconsistent by exposure history of NSAID. H. pylori 
eradication significantly decrease the major complications of 
PU such as bleeding in NSAID-naïve patients with PU history,31 
however, rebleeding rate within 6 months between the H. pylori 
eradicated group and omeprazole maintenance group without 
eradication among long-term naproxen users with a history 
of PU bleeding, was significantly higher in the eradication 
group than the omeprazole group (eradication group 18.8% vs 
omeprazole group 4.4%; absolute difference [95% CI], 14.4% [4.4 
to 24.4]; p=0.005).36 In summary, we recommend that patients 
scheduled for long-term NSAID therapy undergo testing for, and 
treatment of, H. pylori infection. However, the increasing inci-
dence of antibiotic-resistant H. pylori strains is a global trend,37 
and clinicians need to be careful when selecting an eradica-
tion regimen considering that amoxicillin, clarithromycin and 
quinolone-resistant strains are currently significantly increasing 
in several areas.38
Statement 3. We recommend high-risk patients who are tak-
ing long-term NSAID medications receive low-dose PPIs to 
prevent PU and its complications.
Strength of recommendation: strong for, level of evidence: high
Expert opinion: completely agree (78%), mostly agree (18%), 
partially agree (4%), mostly disagree (0%), completely dis-
agree (0%), not sure (0%)
Benefit: preventive effect on PU and its complications
Harm: Potential adverse events of long-term PPI use (e.g., 
fracture, pneumonia, Clostridioides difficile infection, elec-
trolyte imbalance)
Nine RCTs on the preventive effect of PPI co-administration 
for NSAID-induced PU were identified (Supplementary Fig. 
5).32,39-46 Pooled RR (95% CI) for PU development was 0.29 (0.17 
to 0.49) in the <12 weeks of NSAID use, 0.46 (0.19 to 1.14) in 
the 12–24 weeks of NSAID use, and 0.23 (0.17 to 0.49) in the 
≥24 weeks of NSAID use. In other words, co-administration of 
PPIs reduced the risk of PU development by 54% to 76% com-
pared to use of NSAID without PPIs (Supplementary Fig. 6). 
In the subgroup analysis of different doses of PPIs for PU-
preventive effects, standard-dose of PPIs and low-dose (main-
tenance dose) of PPIs were evaluated in five and eight studies, 
respectively (Supplementary Fig. 7). Pooled RR (95% CI) of 
standard-dose PPIs was 0.56 (0.31 to 1.00) and that of low-dose 
PPIs was 0.19 (0.12 to 0.30) (Supplementary Fig. 7). Even low-
dose PPIs had a preventive effect on NSAID-induced PU. Ad-
ditionally, there was no evidence that standard-dose PPIs was 
superior in terms of PU prevention to low-dose. In the subgroup 
analysis of different types of PPIs, preventive efficacy seemed 
to not be different across the types of PPIs, despite insufficient 
studies to reach a definitive conclusion (Supplementary Fig. 8).
Common adverse events of PPIs include diarrhea, nausea, 
vomiting, abdominal pain, and headache; however, most are 
mild and self-limiting.47 Nevertheless, the compliance of PPIs 
is low because they need to be taken before meals.48 Addition-
ally, many observational studies have reported various adverse 
events associated with long-term PPI use, including fracture,49 
pneumonia,50 C. difficile,51 electrolyte imbalance,52 renal dis-
ease,53 dementia,54 myocardial infarction,55 small intestinal 
bacterial overgrowth.56 In most studies, however, the level of 
evidence was low. The benefit of co-administration of PPIs out-
weighs the hazard in high-risk patients for NSAID-induced PU.57 
Nevertheless, the need for long-term NSAID therapy should be 
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periodically reassessed based on individual patient’s clinical 
symptoms given the potential risk of PPIs. If discontinuation of 
NSAIDs is possible, or if potential adverse events such as frac-
ture, pneumonia, C. difficile infection, or electrolyte imbalance 
occur during long-term PPI therapy, the discontinuation of PPIs 
should be considered.
The effect of PPIs for prevention of NSAID-induced PU has 
been proven through RCTs with low-risk of bias. Significant 
heterogeneity was identified in several studies with ≥24 weeks 
of NSAID use; however, the preventive effect of PPIs was con-
firmed in all those studies. Additionally, heterogeneity was not 
identified in studies with <12 weeks of NSAID use, and those 
with 12–24 weeks of NSAID use. Although there are potential 
adverse events related to long-term PPI therapy, the beneficial 
effect of co-administration of PPIs is greater than the potential 
risks in high-risk patients for NSAID-induced PU. Taken togeth-
er, we recommend that high-risk patients who are taking long-
term NSAID medications receive low-dose PPIs to prevent PU 
and its complications. However, the comparison of preventive 
effects between PPI dosages was derived from subgroup meta-
analysis without direct comparative studies. Additionally, dose-
dependent efficacy was not fully evaluated in all types of PPIs. 
It is difficult to conclude that the use of standard-dose PPIs is 
more harmful than that of low-dose PPIs. Therefore, low-dose 
PPIs may be considered primarily; however, standard-dose of 
PPIs may be used based on clinical needs.
1) Preventive effect of misoprostol in patents with long-
term NSAID use
The preventive effect of misoprostol for NSAID-induced PU 
has been reported in 12 RCTs (Supplementary Fig. 9).58-69 Co-
administration of misoprostol with NSAIDs reduced the risk of 
PU development by 55% to 74% compared to administration of 
NSAIDs alone (Supplementary Fig. 10). The effect size of miso-
prostol for the prevention of NSAID-induced PU was similar to 
that of PPIs. Depending on the duration of NSAIDs, the preven-
tion effects on PU before 12 weeks, 12–24 weeks, and 24 weeks 
or later were reported in seven, five, and two studies, respec-
tively. The pooled RR (95% CI) was 0.31 (0.20 to 0.47) in the 
<12 weeks, 0.26 (0.18 to 0.38) in the 12–24 weeks, and 0.45 (0.26 
to 0.41) in the ≥24 weeks of duration. There was no significant 
difference in the preventive effects of PUs even if the duration 
of administration was extended.
In the subgroup analysis of misoprostol dosage, pooled RR of 
400–600 μg of misoprostol was 0.32 (95% CI, 0.22 to 0.47) in 
eight studies, and that of 800 μg of misoprostol was also 0.32 
(95% CI, 0.22 to 0.47) in five studies. There was no significant 
difference of preventive effect between the misoprostol dosages 
(Supplementary Fig. 11). Taken together, we can use misopro-
stol in high-risk patients who take NSAIDs who require long-
term PPI therapy. However, we should consider the adverse 
GI events of misoprostol. In the previous meta-analysis on the 
efficacy and adverse events of misoprostol in NSAID users, diar-
rhea, abdominal pain, and nausea increased by 36%, 36%, and 
26%, respectively, compared to placebo.70 Moreover, discontinu-
ation of misoprostol caused by adverse events increased by 41% 
compared to placebo.70 Considering GI adverse events and low 
drug compliance of misoprostol, we recommend PPIs primarily 
for the PU prevention. However, misoprostol can be used if it is 
difficult to administer PPIs.
The statement, “We recommend high-risk patients who are 
taking long-term NSAID medications receive 400–600 μg of 
misoprostol to prevent PU and its complications,” formulated by 
the Development Committee, has not been finally adopted as a 
recommendation because it failed to obtain consent from more 
than two-thirds of the respondents in the first and second votes.
2) Preventive effect of H2RA in patents with long-term 
NSAID use
There were seven RCTs on the preventive effect of H2RA for 
NSAID-induced PU (Supplementary Fig. 12).71-77 Co-administra-
tion of H2RA with NSAIDs reduced the risk of PU development 
by 33% to 68% compared to administration of NSAIDs alone 
(Supplementary Fig. 13). Although co-administration of H2RA 
had a significant effect for the prevention of PU, the effect size 
of H2RA was relatively small compared to co-administration of 
PPIs or misoprostol.
Depending on the duration of NSAIDs, the prevention ef-
fects on PUs before 12 weeks, 12–24 weeks, and 24 weeks or 
later were reported in two, two, and five studies, respectively. 
The pooled RR (95% CI) was 0.32 (0.16 to 0.64) for <12 weeks, 
0.67 (0.45 to 1.02) for 12–24 weeks, and 0.51 (0.41 to 0.64) for 
≥24 weeks of duration (Supplementary Fig. 13). Although it is 
difficult to provide a definitive conclusion due to the limited 
number of studies and participants, the studies by Frank et al.72 
and Hudson et al.,76 that reported the preventive effect of H2RA 
at 2 and 4 weeks, respectively, showed large effect sizes (RR, 
0.26; 95% CI, 0.09 to 0.74 and RR, 0.37; 95% CI, 0.15 to 0.95, 
respectively), whereas other studies that reported the preven-
tive effect at 12–24 weeks or ≥24 weeks demonstrated relatively 
small effect sizes (12–24 weeks: RR, 0.67; 95% CI, 0.45 to 1.02; 
≥24 weeks: RR, 0.51; 95% CI, 0.41 to 0.64). These findings may 
imply that tachyphylaxis, which is a rapid reduction in the 
gastric acid-inhibitory effect of H2RA, occurs after repeated 
administration. In a study on the gastric acid-inhibitory effect 
of 20 mg of famotidine and 20 mg of omeprazole, the propor-
tion with intragastric pH >4 was 46.9% with famotidine and 
44.6% with omeprazole at the first day of administration, 35.7% 
with famotidine and 57.2% with omeprazole at the third day, 
and 33.6% with famotidine and 63.1% with omeprazole at the 
14th day.78 In other words, the gastric acid-inhibitory effect 
of famotidine rapidly diminished with time. In the review of 
tachyphylaxis of H2RA, tachyphylaxis occurred with most types 
of H2RAs within 2–14 days.79 Although one study reported that 
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tachyphylaxis occurred at 4 weeks after H2RA, the study com-
pared intragastric pH only between day-1 and week-4. In fact, 
in most cases, tachyphylaxis is thought to occur within 2 weeks. 
However, the gastric acid-inhibitory effect of H2RA does not 
completely disappear despite the tachyphylaxis, and preventive 
effects of H2RA for NSAID-induced PU was identified even in 
studies with ≥24 weeks of administration. Therefore, H2RA may 
be considered if it is difficult to administer PPIs or misoprostol.
In a subgroup analysis of H2RA dosage, pooled RR of stan-
dard-dose of H2RA was 0.59 (95% CI, 0.40 to 0.87) in four stud-
ies, and that of high-dose (double-dose) of H2RA was also 0.50 
(95% CI, 0.40 to 0.63) in five studies. There was no significant 
difference of preventive effect between the H2RA dosages (Sup-
plementary Fig. 14).
The statement, “We recommend high-risk patients who are 
taking long-term NSAID medications receive standard-dose of 
H2RA to prevent PU and its complications,” formulated by the 
Development Committee, has not been finally adopted as a rec-
ommendation. However, it failed to obtain consent from more 
than two-thirds of the respondents in the first and second votes.
Statement 4. In high-risk patients who are taking NSAIDs, 
medications should be chosen considering the risk of car-
diovascular diseases. For patients with high-risk of NSAID-
induced PU and low-risk of cardiovascular diseases, we 
recommend cyclooxygenase-2 (COX-2) inhibitor as NSAID.
Strength of recommendation: strong for, level of evidence: high
Expert opinion: completely agree (40%), mostly agree (36%), 
partially agree (16%), mostly disagree (0%), completely dis-
agree (4%), not sure (4%)
Benefit: preventive effect on PU and its complications
Harm: Potentially increased risk of adverse cardiovascular 
events
Twenty-two RCTs comparing the risk of PU diseases between 
nonselective cyclooxygenase (COX) inhibitor and selective COX-
2 inhibitor have been identified (Fig. 1).80-101 Use of selective 
COX-2 inhibitor reduced the risk of PU development by 73% 
to 80% compared to that of nonselective COX inhibitor (Fig. 
2). The effect size of selective COX-2 inhibitor use was similar 
to that of co-administration of PPIs or misoprostol. In the sub-
group analysis of medication duration, the pooled RR (95% CI) 
of selective COX-2 inhibitor use was 0.17 (0.08 to 0.36) in stud-
ies with <12 weeks, 0.27 (0.23 to 0.33) in studies with 12–24 
weeks, and 0.25 (0.20 to 0.31) in studies with ≥24 weeks. In 
other words, the PU-preventive effect of selective COX-2 inhibi-
tor use was confirmed regardless of the duration of medication 
(Fig. 2).
There was one head-to-head clinical trial comparing selective 
COX-2 inhibitor use and co-administration of PPIs to nonselec-
tive COX inhibitor (Supplementary Fig. 15). In this study, there 
was no significant difference between the groups, although se-
lective COX-2 inhibitor tended to be superior to co-administra-
tion of PPIs with nonselective COX inhibitor (hazard ratio [HR], 
0.70; 95% CI, 0.42 to 1.18) (Supplementary Fig. 16).102 
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Fig. 1. Flowchart of study selection 
for the prevention of peptic ulcers 
with cyclooxygenase-2 inhibitors in 
NSAID users. 
NSAID, nonsteroidal anti-inflam-
matory drug; RCT, randomized con-
trolled trial.
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risk of PU development is advantageous compared to co-admin-
istration of PPIs or misoprostol because it can reduce the risk 
without additional medication. Although unspecific abdominal 
pain, diarrhea, and dyspepsia were reported as common adverse 
events of selective COX-2 inhibitor, they were mild and the 
adverse event-related discontinuation rate of selective COX-2 
inhibitor was significantly lower than that of nonselective COX 
inhibitor.83 However, attention should be paid to use in patients 
with high-risk of cardiovascular diseases, as selective COX-2 
inhibitor can increase the risk of adverse cardiovascular events. 
According to the meta-analysis on adverse events associated 
with selective COX-2 inhibitors, this drug category increased 
the risk of myocardial infarction by 53% and tended to increase 
the risk of vascular events (RR, 1.16; 95% CI, 0.97 to 1.36).103 
5.1.1 <12 weeks
Roth 1994, GD, 4 wk
Laine 1995, GD, 1 wk
Laine 1995, GD, 4 wk
Porto 1998, GD, 4 wk
Goldstein 2003, GD, 1 wk
Hawkey 2003, GD, 6 wk
Hunt (AJG) 2003, GD, 6 wk
Rordorf 2003, GD, 1 wk
Girawan 2004, GD, 3 wk
Scheiman, 2004, GD, 10 d
Goldstein 2006, GD, 1 wk
Moberly 2007, GD, 1 wk
Sakamoto 2013, GD, 2 wk
Subtotal (95% CI)
Total events
Heterogeneity: Tau =0.68, Chi =27.33, df=12 (p=0.007); I =56%
Test for overall effect: Z=4.67 (p<0.00001)
5.1.2 12 24 weeks
Roth 1994, GD, 12 wk
Laine 1999, GD, 12 wk
Simon 1999, GD, 12 wk
Hawkey 2000, GD, 12 wk
Hawkey 2001, GD, 12 wk
Kivitz 2002, GD, 12 wk
Sikes 2002, GD, 12 wk
Hawkey 2003, GD, 12 wk
Hunt (AJG) 2003, GD, 12 wk
Hunt (APT) 2003, GD, 12 wk
Hawkey 2004, GD, 13 wk
Kivitz 2004, GD 13 wk
Subtotal (95% CI)
Total events
Heterogeneity: Tau =0.02, Chi =14.11, df=11 (p=0.23); I =22%
Test for overall effect: Z=14.60 (p<0.00001)
5.1.3 >24 weeks
Roth 1994, GD, 24 wk
Roth 1994, GD, 52 wk
Emery 1999, GD, 24 wk
Laine 1999, GD, 24 wk
Hawkey 2000, GD, 24 wk
Subtotal (95% CI)
Total events
Heterogeneity: Tau =0.00, Chi =0.59, df=4 (p=0.96); I =0%
Test for overall effect: Z=12.58 (p<0.00001)
Total (95% CI)
Total events
Heterogeneity: Tau =0.04, Chi =40.19, df=29 (p=0.08); I =28%
Test for overall effect: Z=16.53 (p<0.00001)
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Fig. 2. The preventive effect of selective COX-2 inhibitors on gastroduodenal ulcers in long-term NSAID users. Forest plot, COX-2 versus placebo 
(subgroup analysis by assessment timing). 
G, gastric ulcer; D, duodenal ulcer; NSAID, nonsteroidal anti-inflammatory drug; COX-2, cyclooxygenase-2; CI, confidence interval; M-H, Mantel 
Haenszel.
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Therefore, if patients at high-risk of NSAID-induced PU have a 
low risk of cardiovascular disease, selective COX-2 inhibitor can 
be used for prevention of PU and its complications.
The NSAID-induced PU-preventive effect of selective COX-2 
inhibitor at durations of 12–24 weeks as well as ≥24 weeks has 
been proven in RCTs with low risk of bias. There is the potential 
for adverse cardiovascular events in patients with risk of cardio-
vascular diseases; however, for patients with low-risk of cardio-
vascular diseases, we strongly recommend the use of selective 
COX-2 inhibitor instead of nonselective COX inhibitor because 
its beneficial effect outweighs the harmful.
1) Strategy for prevention of PU and its complications in 
patients who are taking long-term NSAID
Strategies for prevention of PU and its complications in 
patients who are taking long-term NSAID can be determined 
based on the GI risk and the cardiovascular risk (Table 3). Non-
selective COX inhibitor without co-administration of other drugs 
can be chosen for patients with low-risk of NSAID-induced PU 
and low-risk of cardiovascular diseases. Patients with high-risk 
of cardiovascular diseases even though they have no PU risk in-
cluding aging, may need administration of aspirin, antiplatelet 
agents, or anticoagulant. Because the risk of PU or ulcer bleed-
ing is high in those patients, they require co-administration of 
PPIs when NSAIDs are administered. If patients have high GI 
risk but low cardiovascular risk, selective COX-2 inhibitors may 
be chosen as NSAIDs. Co-administration of PPIs to nonselective 
COX inhibitor is also expected to have a similar preventive ef-
fect as a selective COX inhibitor without PPIs.
If both the GI and cardiovascular risks are high, avoid using 
NSAIDs if possible. However, if NSAIDs are unavoidable, it is 
recommended to use nonselective NSAIDs with PPIs. If it is also 
difficult to administer PPIs, co-administration of misoprostol to 
nonselective NSAIDs may be considered while paying attention 
to adverse GI events including diarrhea. Otherwise, co-adminis-
tration of H2RA to NSAIDs may be chosen even though its PU-
preventive effect is relatively low. 
Statement 5. We recommend that patients who have a his-
tory of PU receiving long-term LDA therapy undergo treat-
ment for H. pylori infection in order to prevent PU and its 
complications.
Strength of recommendation: strong for, level of evidence: low
Expert opinion: completely agree (33%), mostly agree (46%), 
partially agree (21%), mostly disagree (0%), completely dis-
agree (0%), not sure (0%)
Benefit: preventive effect on PU and its complications
Harm: increase of antibiotic-resistant H. pylori strains
Two studies showed the effect of H. pylori eradication for 
reductions in PU and its complications (Supplementary Fig. 17), 
one of which was an RCT and the other a prospective cohort 
study.36,104 Chan et al.36 reported that the rebleeding rate for 6 
months between an H. pylori eradicated group and an omepra-
zole maintenance group without eradication among LDA users 
with a history of PU bleeding, was not significantly different 
between the two groups (absolute difference [95% CI], 1.0% 
[–1.9 to 3.9]; p>0.05). In a prospective cohort study, the authors 
recruited three cohorts of long-term LDA users (H. pylori eradi-
cated cohort which contained H. pylori-positive users with PU 
bleeding history and H. pylori eradication; H. pylori negative 
cohort which contains H. pylori negative users with PU bleed-
ing history; and an average cohort which contained new LDA 
users without PU history), and followed up ulcer bleeding for 10 
years. The incidence rate ratio (IRR) of ulcer bleeding was not 
significantly different between H. pylori-eradicated cohort and 
Table 3. Recommendations Regarding NSAID Use According to the Risk of NSAID-Induced Ulcer and Cardiovascular Disease
Risk of NSAID-induced ulcer or complication
Low High
- Old age
- Peptic ulcer history
- Use of high dose of NSAID
- Concomitant use of aspirin, antiplatelet agent, antico-
agulant, or steroid
Risk of cardiovascular disease Low Use nonselective COX inhibitors (1) Use selective COX-2 inhibitors, or
(2) Add proton pump inhibitors to nonselective COX 
inhibitors
High* Add proton pump inhibitors to nonse-
lective COX inhibitors
(1) Avoid NSAIDs, if possible
(2) Add proton pump inhibitors to nonselective COX 
inhibitors, if NSAIDs cannot be stopped
NSAID, nonsteroidal anti-inflammatory drug; COX, cyclooxygenase.
*Aspirin, antiplatelet agent, or anticoagulant users for the prevention of serious cardiovascular events.
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average risk cohort, if patients take LDA only (IRR for H. pylori-
eradicated cohort, 0.97; 95% CI, 0.53 to 1.80; IRR for average 
risk cohort, 0.66; 95% CI, 0.38 to 0.99).104 However, concomi-
tant use of other antiplatelet agents or anticoagulants with LDA 
markedly increased the IRR in the H. pylori-positive cohort 
(IRR, 7.01; 95% CI, 2.25 to 21.89), an effect which was reduced 
by co-administration of anti-ulcer drugs (IRR, 5.96; 95% CI, 
0.62 to 57.34).104 Meanwhile, an RCT showed the effect of PPI 
maintenance after H. pylori eradication. The authors recruited 
H. pylori-infected LDA users with a history of PU bleeding and 
randomized the patients after eradication as a placebo group 
and a lansoprazole maintenance group, and followed up for 
12 months. Recurrence of ulcer complications such as bleeding 
was significantly lower in the lansoprazole maintenance group 
than the observation group (placebo group: 14.8%, lansoprazole 
maintenance group: 1.6%; adjusted HR, 10.6; 95% CI, 1.3 to 
86.1; p=0.008), which showed that lansoprazole maintenance 
after eradication significantly reduced the recurrence of bleed-
ing.105
In summary, H. pylori eradication is effective for reducing 
the recurrence of PU complications such as bleeding among 
long-term LDA users with a history of PU bleeding, however, 
maintenance of anti-ulcer drugs such as PPI is necessary after 
eradication, if patients concomitantly use drugs that can cause 
upper GI bleeding such as other antiplatelet agents or antico-
agulants (Fig. 3). It was necessary to downgrade the level of 
evidence from a high level on the categories of consistency and 
precision, considering that the number of studies was lacking 
and a searched RCT could not show the superiority of eradica-
tion alone over PPI maintenance in terms of the preventive ef-
fect of rebleeding. However, the Development Committee finally 
decided to recommend that patients with a history of PU and 
bleeding receiving LDA therapy, undergo diagnosis and treat-
ment for H. pylori infection, judging that on balance, the pa-
tient’s benefits are greater than the harms.
Statement 6. We recommend that patients who have a his-
tory of PU receiving long-term LDA therapy are co-admin-
istered PPI to prevent PU and rebleeding.
Strength of recommendation: strong for, level of evidence: 
moderate
Expert opinion: completely agree (44%), mostly agree (48%), 
partially agree (4%), mostly disagree (4%), completely dis-
agree (0%), not sure (0%)
Benefit: preventive effect on PU and its complications
Harm: potential adverse events of long-term PPI use (i.e., 
fracture, pneumonia, C. difficile infection, electrolyte im-
balance)
Effects of PPI on prevention of recurrent PU and its complica-
tions in patients who require long-term use of LDA (75–325 mg/
day) have been reported in a total of seven RCTs (Supplementary 
Fig. 18).105-111 A meta-analysis of the seven RCTs included 5,181 
patients (3,112 patients with concomitant aspirin and PPI use; 
2,069 patients with aspirin alone or aspirin with control drug), 
and the duration of treatment ranged from 12 to 72 weeks. The 
concomitant use of PPIs and aspirin compared with the control 
group reduced the occurrence PU by 83% (HR, 0.17; 95% CI, 
0.12 to 0.25; p<0.00001) (Supplementary Fig. 19A), with risk 
difference of –0.13 (95% CI, –0.1 to –0.08; p<0.00001), and 
number needed to treat (NNT) of 7.7 (Supplementary Fig. 19B). 
In the subgroup analysis of patients with GU (Supplementary 
Fig. 20), DU (Supplementary Fig. 21), and ulcer bleeding (Sup-
plementary Fig. 22), concomitant PPI and aspirin use compared 
with control groups reduced the incidence of GU, DU, and ulcer 
bleeding by 78% (HR, 0.22; 95% CI, 0.13 to 0.35; p<0.00001), 
91% (HR, 0.09; 95% CI, 0.03 to 0.25; p<0.00001), and 83% (HR, 
0.17; 95% CI, 0.07 to 0.45; p<0.0004), respectively, and the risk 
difference was –0.11 (95% CI, –0.16 to –0.06; p<0.0001, NNT of 
9.1), –0.04 (95% CI, –0.06 to –0.02; p<0.0001, NNT of 25), and 
–0.03 (95% CI, –0.08 to –0.01; p<0.10), respectively. In sum-
mary, PPI reduced the recurrence of PU and bleeding in patients 
requiring long-term use of LDA.
However, concomitant use of PPIs in all patients taking as-
pirin with a history of PU should be evaluated clinically, con-
sidering the benefits and risks of long-term administration. The 
studies included in the meta-analysis defined PUs as mucosal 
injuries or defects of 3 mm or more, suggesting that a signifi-
History of PUB
Successful eradication PPI co-therapy
PPI co-therapy is not necessaryHelicobacter pylori infection
LDA user for secondary prevention
NoYes
Yes No
Fig. 3. Therapeutic algorithm for 
LDA users with a history of PUB. 
LDA, low-dose aspirin; PUB, peptic 
ulcer bleeding; PPI, proton pump 
inhibitor.
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cant number of patients with erosive or mild PUs that were not 
clinically significant were included in the study. In addition, Lai 
et al.105 reported that in patients who had ulcer complications 
associated with long-term use of LDA, the placebo group as 
compared with the lansoprazole group showed recurrent ulcer 
complications with adjusted HR of 9.6 (95% CI, 1.2 to 76.1; 
p=0.008, 1.6% vs 14.8%). However, of these 10 patients with 
ulcer complications, four had H. pylori infection and two had 
taken NSAIDs. Therefore, in patients on long-term use of LDA 
with a history of PU, concomitant use of PPIs is recommended 
according to the severity of PU. In cases of recurrent PU or tak-
ing antiplatelet or anticoagulant drugs other than aspirin,104 it 
is recommended to use PPIs with the clinical judgment of the 
attending physician.
Statement 7. We recommend restarting aspirin as soon as 
possible for patients receiving aspirin for secondary cardio-
vascular or cerebrovascular prophylaxis, once PU bleeding 
has been successfully controlled with endoscopic hemosta-
sis.
Grade of recommendation: strong, Level of evidence: moderate
Experts’ opinion: completely agree (74%), mostly agree (26%), 
partially agree (0%), mostly disagree (0%), completely dis-
agree (0%), not sure (0%)
Benefit: effect on reducing major cardiovascular death
Harm: risk of rebleeding
There is very limited evidence in the literature to guide proper 
timing of restarting antiplatelet agents in patients with PU 
bleeding who were taking antiplatelet agents. There was only 
one RCT that evaluated the risk of rebleeding and adverse car-
diovascular and cerebrovascular events according to continuing 
or stopping aspirin in patients who were taking LDA when they 
developed PU bleeding (Supplementary Fig. 23).112 This study 
compared stopping aspirin for 8 weeks and restarting aspirin af-
ter endoscopic hemostasis in patients who were taking LDA for 
established cardiovascular or cerebrovascular diseases. In their 
findings, continuing aspirin showed a nonsignificant 2-fold 
increased risk of recurrent ulcer bleeding within 30 days as 
compared with stopping aspirin (aspirin group 10.3% vs placebo 
group 5.4%; absolute difference [95% CI], 4.9% points [–3.6 to 
13.4]). However, continuation of aspirin significantly reduced 
all-cause mortality rates at 8 weeks (aspirin group 1.3% vs pla-
cebo group 12.9%; absolute difference [95% CI], 11.6% points 
[3.7 to 19.5]), which were mainly caused by cardiovascular, 
cerebrovascular, or GI events. It was necessary to downgrade 
the level of evidence to moderate with regard to inconsistency 
and imprecision because there was only one study. However, 
the recommendation grade was high because reduction in the 
risk of death and a key outcome, was significantly greater.
The Japanese Society of Gastroenterology (JSGE) and the 
American Society for Gastrointestinal Endoscopy (ASGE) also 
recommended reintroduction of aspirin immediately after he-
mostasis is achieved.14,113 In an exception to this, the European 
Society of Gastrointestinal Endoscopy (ESGE) recommended 
to withhold aspirin for 3 days in patients with high risk of PU 
bleeding (active bleeding, visible vessels, or adherent clots),114 
because most recurrent bleeding with continuing aspirin devel-
oped within 3 days in the abovementioned study.112 Therefore, 
it is recommended that aspirin should be resumed immediately 
after endoscopic hemostasis in patients who need long-term 
maintenance of aspirin because of major cardiovascular disease.
No RCT was found to guide the timing of resumption of thi-
enopyridine including clopidogrel or dual antiplatelet therapy 
following PU bleeding. Therefore, the recommendation on this 
was made similar to the recommendation on aspirin, an area of 
uncertainty which needs to be revised when further research is 
published in this regard (Table 4).
Statement 8. We recommend restarting anticoagulants as 
soon as possible for patients who need long-term antico-
agulant therapy, once PU bleeding has been successfully 
controlled with endoscopic hemostasis. The timing for 
resumption is determined considering patients’ risks of re-
bleeding and importance of resumption of anticoagulants.
Grade of recommendation: strong, Level of evidence: very low
Experts’ opinion: completely agree (67%), mostly agree (29%), 
partially agree (4%), mostly disagree (0%), completely dis-
agree (0%), not sure (0%)
Benefit: effect on reducing thromboembolism and mortality
Harm: risk of rebleeding
There is little evidence on when and how to restart the anti-
coagulant after PU bleeding in patients taking anticoagulants, 
Table 4. Recommendation Regarding Restarting Antiplatelet Agents According to the Medicine Classification
Patents Antiplatelet agents Recommendation Level of recommendation Level of evidence




Aspirin Restart after endoscopic hemostasis Strong High
Other agents (e.g. P2Y12 
receptor inhibitor)
Restart after endoscopic hemostasis Strong Low
Dual antiplatelet therapy 
(DAPT)
Restart aspirin after endoscopic hemostasis.
Early cardiology consultation for resuming 
the second antiplatelet agent.
Strong Low
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and previous guidelines mentioned this issue based on expert 
opinion (Supplementary Fig. 24). ASGE,113 ESGE114 and Asian-
Pacific guideline115 recommend that resumption of anticoagu-
lant should be made multidisciplinary access by comprehen-
sively considering patient’s status, importance of anticoagulant 
treatment, characteristics of hemorrhagic ulcer lesions, effective 
hemostasis, and risk of rebleeding. Cardiologists assess the 
thromboembolic risk in patients with atrial fibrillation and deep 
vein thrombosis, and endoscopists assess the rebleeding risk in 
GI tract. In principle, we recommended restarting anticoagulants 
immediately after effective hemostasis of ulcer in patients with 
PU bleeding who need long-term use of anticoagulants, if the 
risk of rebleeding is low.
Currently, ESGE114 and Asia-Pacific guideline115 recommend 
the use of vitamin K in patients with warfarin-related severe 
PU bleeding for antagonistic effects to warfarin. A previous 
retrospective study about the optimal timing of warfarin after 
endoscopic hemostasis of PU showed that rapid resumption of 
warfarin significantly reduced the thromboembolic risk.116 The 
risk of thrombosis should be assessed for each patient in order 
to determine the appropriate timing of resumption. Several pre-
vious retrospective studies which included patients with various 
thromboembolic risks117,118 showed that thrombosis and mortal-
ity were reduced without increasing the risk of rebleeding if 
warfarin was restarted within 7 to 30 days, however, rebleeding 
risk increased twice if it was started within 7 days after index 
bleeding. The Asian-Pacific guideline115 recommends restarting 
warfarin with heparin bridge therapy within 3 days of endo-
scopic hemostasis in high thromboembolic risk group, especially 
because it would take time to achieve sufficient anticoagulative 
effect if patients with warfarin use were given antagonists (Table 
5).115,119,120 ESGE guideline114 states that resumption of warfarin 
should be individualized and recommends restarting warfarin 
between 7 to 15 days after index bleeding if possible, however, 
it does not mention anything with regard to heparin bridge 
therapy.114 Asian-Pacific guideline115 recommends intravenous 
administration of unfractionated heparin rather than low-
molecular-weight heparin for heparin bridge therapy, because 
unfractionated heparin has a short half-life (1 to 2 hours) after 
intravenous administration, and it can be stopped quickly if re-
bleeding occurs. 
The use of direct oral anticoagulants (DOAC) in patients with 
PU bleeding may be differently assessed based on the severity 
of bleeding, time taken till the last dose of DOAC, renal function 
and pharmacokinetic characteristics of a given drug. The Asian-
Pacific guideline115 recommends temporally withholding the 
use of DOAC in patients with DOAC-related upper GI bleeding 
considering its short half-life. Vitamin K is not recommended 
due to absence of antagonistic effect for DOAC. Activated char-
coals are considered in patients with unstable vital signs due 
to severe bleeding, if not more than 3 hours after taking DOAC 
because plasma concentrations of DOAC reach their maximum 
after 3 hours of administration. Idarucizumab is considered in 
patients with dabigatran-related severe bleeding. It is not com-
mon for patients taking DOAC to require antagonist, and clini-
cians can continue conservative management while waiting for 
the anticoagulant effect to disappear in most patients. ASGE,113 
ESGE114 and British Society of Gastroenterology (BSG) and 
ESGE guideline121 does not specifically recommend the optimal 
timing of resumption of DOAC after endoscopic hemostasis, and 
Asian-Pacific guideline115 recommends restarting DOAC as soon 
as possible, within 3 days after discontinuation. The residual 
anticoagulant effect in the body decreases to a minimum within 
3 days of discontinuation of DOAC due to its short half-life (12 
hours) except in patients with decreased renal function. In terms 
of heparin bridge therapy till resumption of DOAC, Asian-Pacif-
ic guideline117 does not recommend the bridge therapy consider-
ing the rapid time of action of DOAC (1 to 4 hours), while ESGE 
guideline114 recommends bridge therapy with unfractionated 
heparin or low-molecular-weight heparin rather than immediate 
use of therapeutic dose of DOAC, then restarting the therapeutic 
dose of DOAC after disappearance of rebleeding risk. 
In summary, evidence about optimal timing and method 
of resumption of anticoagulants in patients with PU bleeding 
during long-term use of anticoagulants are severely lacking, 
however, we recommend restarting anticoagulants as soon as 
possible immediately following endoscopic hemostasis of PU 
bleeding for patients who need long-term anticoagulant thera-
Table 5. Indications for Heparin Bridging for the Temporary Discon-
tinuation of Warfarin113
Non-valvular atrial fibrillation with a CHA2DS2-VASc score >5*
Metallic mitral valve
Prosthetic valve with atrial fibrillation
<3 Months after venous thromboembolism 
Severe thrombophilia (protein C or protein S deficiency, antiphos-
pholipid syndrome)
*CHA2DS2-VASc, congestive heart failure (1 point), hypertension (1 
point), age ≥75 years (2 points), diabetes mellitus (1 point), stroke, 
transient ischemic attack, or thromboembolism (2 points), vascular 
disease (1 point), age 65–74 years (1 point), female sex (1 point).117,118
Table 6. Thrombotic Risk According to Cardiac Events113
Thrombotic risk category Cardiac events
Very high ACS or PCI <6 weeks
High ACS or PCI 6 weeks to 6 months ago 
Moderate to low ACS or PCI >6 months ago; stable coronary 
artery disease
New-generation drug-eluting stents and bare-metal stents carry simi-
lar thrombotic risks. The risk is highest within the first 6 weeks after 
PCI. The risk remains high from 6 weeks to 6 months, then remains 
constant thereafter.120,121
ACS, acute coronary syndrome; PCI, percutaneous coronary interven-
tion.
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py. The optimal timing and details of restarting are determined 
by comprehensively considering patients’ rebleeding risk, type 
and pharmacokinetic characteristics of given anticoagulants, 
and thromboembolic risk (Table 6).115,122,123
Statement 9. We suggest high-risk patients who are taking 
anticoagulants to be administered PPIs to prevent upper GI 
hemorrhage.
Strength of recommendation: weak for, level of evidence: low
Expert opinion: completely agree (38%), mostly agree (46%), 
partially agree (16%), mostly disagree (0%), completely dis-
agree (0%), not sure (0%)
Benefit: preventive effect on upper GI hemorrhage
Hazard: low drug adherence, potential adverse events of 
long-term PPI use (e.g., fracture, pneumonia, C. difficile 
infection, electrolyte imbalance)
Six nested case-control or cohort studies (three case-con-
trol124-126 and three cohort studies127-129) which evaluated the pro-
tective effect of acid suppressants against anticoagulant-related 
GI hemorrhage were identified through the systematic review 
(Supplementary Fig. 25). PPI had a protective effect against up-
per GI hemorrhage in patients on dicumarinics (RR, 0.56; 95% 
CI, 0.38 to 0.83; I2, 0%), which means that PPI reduced 44% of 
risk for the dicumarinic-related upper GI hemorrhage compared 
to control (Supplementary Fig. 26).
However, the H2RA did not show the same effect (RR, 0.97; 
95% CI, 0.52 to 1.81; I2, 0%) (Supplementary Fig. 27). Sensitiv-
ity analysis according to the modifiers identified during system-
atic review also showed consistent protective effect of PPIs (RR, 
0.59; 95% CI, 0.37 to 0.95) and nonsignificant protective effect 
of the H2RA (RR, 0.78; 95% CI, 0.38 to 1.64) for dicumarinic-
related upper GI hemorrhage (Supplementary Fig. 28).
Although findings in the meta-analyses suggested the protec-
tive effect of PPIs for the development of dicumarinic-related 
upper GI hemorrhage, this effect was attenuated by or limited 
due to the high baseline risk of GI injury found consistently in 
the enrolled studies.124,126,128,129 Moreover, less potent inhibition 
of gastric acid by H2RA showed a nonsignificant protective ef-
fect, suggesting that baseline ulcerogenic properties (preexistent 
erosion or ulcers on the upper GI tract, H. pylori infection, and 
unrecognized use of NSAIDs or aspirin) of enrolled patients de-
termines the magnitude of the protective effect of acid suppres-
sants on anticoagulant-related upper GI hemorrhage. In contrast 
to NSAIDs or aspirin, anticoagulants are not ulcerogenic drugs. 
Pathophysiologic evidence for anticoagulants in the develop-
ment of GI hemorrhage is scarce. Therefore, the duration, dose, 
and adherence to PPI could not be assessed. Considering that 
PPIs share a common metabolic enzyme (CYP3A4), implying 
that their use might increase the serum concentration of warfa-
rin, some PPIs might accelerate the absorption of warfarin, and 
the combination of some PPIs and the CYP2C19 intermediate 
metabolizer could increase bleeding events.130-133
Only two studies were included in the analysis of acid sup-
pressants on dabigatran-related GI bleeding.127,128 It was impos-
sible to differentiate the location of GI hemorrhage (upper vs 
lower) and type of acid suppressants (PPI vs H2RA). Acid sup-
pressants did not have a protective effect against GI hemorrhage 
in patients on dabigatran (HR, 0.78; 95% CI, 0.44 to 1.37; I2, 
81.8%) (Supplementary Fig. 29).
Interactions from co-administration of PPIs and oral fac-
tor Xa inhibitors (xabans) does not appear to be of significant 
concern based on previous studies.131,134,135 However, the interac-
tion of PPIs and the direct thrombin inhibitor dabigatran was 
reported (low on-treatment level of dabigatran) from recently 
published studies.136-138 Potential adverse events related to the 
long-term use of PPIs is another concern. Therefore, balanc-
ing the risk-benefit approach is still necessary before the co-
prescription of anticoagulants and acid suppressants. 
Based on the evidence above, we suggest high-risk patients 
who are taking anticoagulants to be administered PPIs to pre-
vent upper GI hemorrhage. In cases with PPI and warfarin co-
administration, close monitoring of prothrombin time with dose 
adjustment is needed. In terms of DOAC, little is known about 
risk and benefit of PPI co-administration. Considering the num-
ber of enrolled studies in this systematic review is small and all 
the studies were conducted in a retrospective manner, strength 
of recommendation is weak and the level of evidence is low. In 
the absence of randomized trials demonstrating a lack of bias, 
solid conclusions cannot be drawn. 
CONCLUSION
The incidence of drug-related PU and its complications are 
expected to continue to increase due to the aging of the do-
mestic population and the increase in prevalence of major co-
morbidities, which will not only seriously threaten the health of 
elderly patients, but also increase the mortality rate, and likely 
result in huge costs in medical expenses nationwide.139 There-
fore, publishing and disseminating the appropriate clinical prac-
tice guidelines for patients with drug-related PU is an extremely 
valuable task, not only in terms of medical development but 
also in the pursuit of social public interest through health pro-
motion. In the future, it will be necessary to perform additional 
major literature searches to better define the characteristics 
and optimal management of drug-related PU, and revise clini-
cal practice guidelines to keep pace with the rapidly changing 
medical environment.
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